• Kite Pharma (pioneer of CAR-T cell therapy) for solid tumor cancers.

• Lifileucel: A lead product candidate undergoing Phase 2 clinical studies for the treatment of metastatic melanoma and recurrent, metastatic, or persistent cervical cancer.
• LN-145: A product candidate in Phase 2 clinical studies for recurrent and/or metastatic head and neck squamous cell carcinoma.

Iovance Biotherapeutics (IOVA) is described as a "clinical-stage biotechnology company." This means that the company is primarily focused on the research, development, and clinical trials of its drug candidates, such as lifileucel and LN-145, which are currently in Phase 2 clinical studies. As a clinical-stage company, Iovance Biotherapeutics is not yet selling commercialized products to generate revenue from customers in the traditional sense (e.g., direct sales to individuals, hospitals, or pharmacies).

Therefore, Iovance Biotherapeutics does not currently have major customers for commercial products.

Frederick G. Vogt, Ph.D., J.D. – Interim CEO, President and General Counsel

Dr. Vogt joined Iovance in September 2016 as General Counsel. He has served as Interim CEO and President since May 2021 and was elected to the board of directors in June 2024. He possesses over 20 years of experience within the pharmaceutical and biopharmaceutical industries. Before his tenure at Iovance, Dr. Vogt practiced law at Morgan, Lewis & Bockius, an international firm, where his focus was on intellectual property and business law within the life sciences sector.

Corleen Roche – Chief Financial Officer

Ms. Roche joined Iovance in August 2025. She brings an extensive track record of 30 years of experience in the biotech and life sciences industry, including executive financial leadership roles in publicly traded companies. Most recently, she served as CFO of CG Oncology, a late-stage clinical biopharmaceutical company. Her previous roles include CFO of Immunome, U.S. CFO at Biogen, North America CFO of CSL Behring, and various CFO positions within Sandoz, Wyeth, and Pfizer. Throughout her career, Ms. Roche has been instrumental in developing and executing financial strategies to support the commercial launches of several significant products.

Igor Bilinsky, Ph.D. – Chief Operating Officer

Dr. Bilinsky joined Iovance in March 2021. He has over 20 years of cumulative leadership experience, having served as Chief Executive Officer, Chief Operating Officer, and Chief Business Officer at various companies in the life sciences industry. Prior to Iovance, he was the Chief Business Officer of Oncternal Therapeutics, where he played a key role in building the publicly traded oncology company. Dr. Bilinsky also previously held positions as Chief Operating Officer of AmpliPhi Biosciences and as General Manager of Immuno-oncology and Senior Vice President at IGNYTA (which is now part of Roche).

Friedrich Graf Finckenstein, M.D. – Chief Medical Officer

Dr. Graf Finckenstein joined Iovance in July 2019. He is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development within the biopharmaceutical industry. Before joining Iovance, he was the Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland, where he directed all clinical development aspects in the Oncology Discovery and Translational area.

Dan Kirby – Chief Commercial Officer

Mr. Kirby joined Iovance in February 2025 as Chief Commercial Officer, bringing substantial experience in commercial operations, including in cell therapy. Before Iovance, he led global commercial strategy and operations for an emerging cell therapy platform of products as Chief Commercial Officer of Orca Bio. From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation, where he oversaw U.S. and EU launch readiness for narsoplimab and managed all commercial activities for their marketed product, Omidria.

1. Complex Manufacturing and Commercialization Challenges Leading to Profitability Concerns

   The autologous nature of Amtagvi, a tumor-infiltrating lymphocyte (TIL) cell therapy, requires a highly intricate and individualized manufacturing process, taking approximately 34 days from cell collection to infusion. This process involves collecting a patient's own cancer-fighting cells, preparing the medicine for each patient, and administering it at dedicated centers staffed by trained specialists. This inherent complexity drives high production costs and results in thin gross margins, complicating the company's ability to achieve widespread commercial uptake and sustainable profitability. Iovance has experienced slower-than-expected revenue growth for Amtagvi and has revised its revenue guidance downward, reflecting these operational hurdles.

2. Financial Sustainability and Shareholder Dilution

   As a clinical-stage biotechnology company with a newly approved, yet complex, commercial product, Iovance Biotherapeutics continues to incur significant net losses and exhibits a high cash burn rate. The company's financial position often necessitates securing additional capital to fund its operations, ongoing clinical trials, and commercialization efforts. This frequently involves issuing new stock, which can lead to substantial dilution for existing shareholders.

3. Clinical Development and Regulatory Hurdles, Coupled with Competitive Pressures

   Despite the accelerated FDA approval for Amtagvi in advanced melanoma, Iovance faces ongoing clinical development risks for expanding the therapy's label to other cancer indications and for advancing its pipeline candidates. Regulatory hurdles remain significant, as demonstrated by the withdrawal of its Marketing Authorization Application for Amtagvi in the European Union due to misalignment in clinical data. Moreover, the oncology treatment market is intensely competitive, with numerous companies developing novel cancer therapies. Strong clinical data or regulatory progress from competitors could challenge Amtagvi's market position and limit its future growth potential.

Iovance Biotherapeutics (IOVA) focuses on developing and commercializing cancer immunotherapy products. The addressable markets for their main product candidates are as follows:

• Lifileucel for Metastatic Melanoma: The global metastatic melanoma therapeutics market is estimated to be valued at approximately USD 8.00 billion in 2025 and is projected to reach USD 18.02 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032. North America is a significant region in this market, expected to account for a market share of 38.7% in 2025.

• Lifileucel for Recurrent, Metastatic, or Persistent Cervical Cancer: The global cervical cancer treatment market size was estimated at USD 8.16 billion in 2023 and is projected to reach USD 11.74 billion by 2030, exhibiting a CAGR of 5.4% from 2024 to 2030. In 2023, the cervical cancer market size across the 7 Major Markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was approximately USD 930 million. Specifically, the U.S. market accounted for nearly USD 530 million in 2023 and is projected to reach USD 4.8 billion by 2032.

• LN-145 for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: The global head and neck cancer therapeutics market size was estimated at USD 2.65 billion in 2025 and is projected to reach USD 8.14 billion by 2035, with a CAGR of 11.87% between 2026 and 2035. North America held approximately 45% of the revenue share in this market in 2024. For the 7 Major Markets (7MM), the recurrent head and neck squamous cell carcinoma market reached USD 1.6 Billion in 2024 and is expected to reach USD 3.8 Billion by 2035, exhibiting a growth rate of 7.97% during 2025-2035.

1. Commercial Expansion of Amtagvi (lifileucel) in Advanced Melanoma: The company expects significant revenue growth from increased adoption and broader utilization of Amtagvi, which received FDA accelerated approval in February 2024 for unresectable or metastatic melanoma. This growth is anticipated to be fueled by the expansion of its network of Authorized Treatment Centers (ATCs), including larger community practices, which are expected to accelerate Amtagvi adoption and patient referrals. Real-world data showing a strong response rate for Amtagvi is also expected to boost physician confidence and uptake. Management has projected Amtagvi to achieve at least $1 billion in peak U.S. sales.
2. Launch and Expansion into New Indications, Primarily Non-Small Cell Lung Cancer (NSCLC): A significant driver of future revenue growth is the potential expansion of lifileucel into new indications. The market opportunity for lifileucel in non-small cell lung cancer (NSCLC) is estimated to be up to seven times larger than that for melanoma. Lifileucel has already received FDA Fast Track designation for previously treated non-squamous NSCLC, and Iovance is advancing a registrational trial for this indication. A potential launch in NSCLC is projected for the second half of 2027.
3. International Market Expansion for Amtagvi: Iovance is actively pursuing the global commercialization of Amtagvi. The therapy received approval from Health Canada for advanced melanoma in August 2025, marking the company's first marketing authorization outside the United States, with plans to establish treatment centers soon thereafter. Furthermore, Iovance is preparing for additional international expansion, with pending approvals for Amtagvi expected in the U.K. and Australia in the first half of 2026. Significant revenue contributions from these international markets are anticipated to commence in 2027.
4. Continued Sales Growth of Proleukin: Proleukin, another product in Iovance's portfolio, is expected to contribute to revenue growth. The company anticipates an acceleration in Proleukin sales throughout 2025, driven by restocking to U.S. distributors and increasing sales to manufacturers for various clinical and manufacturing uses. Proleukin represented approximately 17% of total product revenue in 2025.

Share Issuance

• Iovance utilized an at-the-market (ATM) equity financing facility, raising approximately $450.0 million in net proceeds during the fourth quarter of 2022 and the first quarter of 2023.
• The company established a new $350 million ATM facility with Jefferies in August 2025 to fund the Amtagvi launch and ongoing clinical trials, which introduced immediate dilution risk.
• Approximately 22.6 million shares were sold through its ATM facility in the first two months of 2025, contributing to an increased cash position.

Outbound Investments

• Iovance Biotherapeutics planned for the acquisition of Proleukin, an interleukin-2 product, with funding for this acquisition expected to be supported by proceeds from its at-the-market equity financing facility.

Capital Expenditures

• Iovance is making significant capital commitments towards innovation and expansion, particularly in enhancing its manufacturing capabilities.
• The Iovance Cell Therapy Center (iCTC) has an annual capacity to supply TIL therapies for over 2,000 patients, with available shell space designed for expansion to support more than 5,000 patients annually.
• A strategic transition of all Amtagvi and clinical manufacturing to the iCTC in early 2026 is underway, aiming to maximize capacity utilization, lower manufacturing costs, and drive future gross margin growth.